Drug research

ARO-APOC3

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Plozasiran

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaNCT04998201	Arrowhead Pharmaceuticals	Phase 2	Completed	2023-02-10Actual
Study of ARO-APOC3 in Adults With DyslipidemiaNCT05413135	Arrowhead Pharmaceuticals	Phase 2	Completed	2025-09-22Actual
Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaNCT04720534	Arrowhead Pharmaceuticals	Phase 2	Completed	2023-03-09Actual

Arrowhead PharmaceuticalsCompletedPrimary completion: 2023-02-10 · Actual

Trial details

Arrowhead PharmaceuticalsCompletedPrimary completion: 2025-09-22 · Actual

Trial details

Arrowhead PharmaceuticalsCompletedPrimary completion: 2023-03-09 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.